Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma

E-ISSN： 1873-4294|12|1|61-66

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.12, Iss.1, 2012-01, pp. : 61-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New therapies in the treatment of melanoma

By Davar Diwakar Kirkwood John Munn

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 11, 2012-11 ,pp. : 1643-1659

Informa Healthcare

Access to resources Recommend Favorite

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

By Ascierto Paolo A. Margolin Kim

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1617-1619

Blackwell Publishing

Access to resources Recommend Favorite

CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-06 ,pp. : 572-585

Bentham Science Publishers

Access to resources Recommend Favorite

New Insights of CTLA-4 into Its Biological Function in Breast Cancer

Current Cancer Drug Targets, Vol. 10, Iss. 7, 2010-11 ,pp. : 728-736

Bentham Science Publishers

Access to resources Recommend Favorite

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

By Camacho Luis H

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 371-385

Informa Healthcare

Access to resources Recommend Favorite